MedTrace Logo

Dimiracetam in Painful Neuropathies Affecting AIDS Patients

NCT01444690 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2011-10-03

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and tolerability of orally administered dimiracetam for 10 weeks to AIDS patients under treatment with antiretroviral agents presenting a disease and /or treatment related neuropathic pain.

Conditions

  • Acquired Immunodeficiency Syndrome

Interventions

DRUG

Dimiracetam

Capsules for oral administration twice daily

DRUG

Dimiracetam 25 mg

Inactive dose level in capsules administered orally twice daily

Sponsors & Collaborators

  • Neurotune AG

    lead INDUSTRY

Principal Investigators

  • Rugerro Fariello, MD · Neurotune AG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01444690 on ClinicalTrials.gov